CN102089009B - 偶联的Vi糖 - Google Patents
偶联的Vi糖 Download PDFInfo
- Publication number
- CN102089009B CN102089009B CN2009801278952A CN200980127895A CN102089009B CN 102089009 B CN102089009 B CN 102089009B CN 2009801278952 A CN2009801278952 A CN 2009801278952A CN 200980127895 A CN200980127895 A CN 200980127895A CN 102089009 B CN102089009 B CN 102089009B
- Authority
- CN
- China
- Prior art keywords
- conjugate
- crm
- protein
- references
- carbodiimide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0810894.6A GB0810894D0 (en) | 2008-06-13 | 2008-06-13 | Conjugated saccharide |
GB0810894.6 | 2008-06-13 | ||
PCT/IB2009/006285 WO2009150543A2 (en) | 2008-06-13 | 2009-06-12 | Conjugated vi saccharides |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102089009A CN102089009A (zh) | 2011-06-08 |
CN102089009B true CN102089009B (zh) | 2013-12-04 |
Family
ID=39672273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801278952A Active CN102089009B (zh) | 2008-06-13 | 2009-06-12 | 偶联的Vi糖 |
Country Status (18)
Country | Link |
---|---|
US (2) | US20110142876A1 (zh) |
EP (1) | EP2303333B1 (zh) |
CN (1) | CN102089009B (zh) |
AU (1) | AU2009259017B2 (zh) |
BR (1) | BRPI0915517B8 (zh) |
CA (1) | CA2727565C (zh) |
CY (1) | CY1116379T1 (zh) |
DK (1) | DK2303333T3 (zh) |
ES (1) | ES2537019T3 (zh) |
GB (1) | GB0810894D0 (zh) |
HR (1) | HRP20150527T1 (zh) |
HU (1) | HUE025512T2 (zh) |
NZ (1) | NZ590089A (zh) |
PL (1) | PL2303333T3 (zh) |
PT (1) | PT2303333E (zh) |
SI (1) | SI2303333T1 (zh) |
WO (1) | WO2009150543A2 (zh) |
ZA (1) | ZA201009304B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120761B (zh) * | 2010-12-24 | 2013-02-06 | 新疆维吾尔自治区畜牧科学院兽医研究所 | 一种无荚膜型金黄色葡萄球菌胞外多糖-蛋白质偶联物的制备方法 |
WO2013038375A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Methods for making saccharide-protein glycoconjugates |
US10046039B2 (en) * | 2013-08-24 | 2018-08-14 | Bharat Biotech International Limited | Bacterial vaccine and methods for manufacture thereof |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
EP3448424A4 (en) * | 2016-04-25 | 2019-10-02 | National Institute of Immunology | NOVEL CONJUGATE FOR THE VACCINATION OF TYPHUS WITH CHEMICAL CONJUGATE OF VI-POLYSACCHARIDE AND FLAGELLIN, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION WITH THE CONJUGATE |
CA3033364A1 (en) | 2016-09-02 | 2018-03-08 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
CN114728051A (zh) | 2019-11-22 | 2022-07-08 | 葛兰素史克生物有限公司 | 细菌糖糖缀合物疫苗的剂量和施用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5738855A (en) | 1994-10-17 | 1998-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
AU2000278267A1 (en) * | 2000-09-01 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vibrio cholerae o139 conjugate vaccines |
AU2002309259A1 (en) * | 2002-05-09 | 2003-11-11 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
PL2066344T3 (pl) * | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
-
2008
- 2008-06-13 GB GBGB0810894.6A patent/GB0810894D0/en not_active Ceased
-
2009
- 2009-06-12 PL PL09762071T patent/PL2303333T3/pl unknown
- 2009-06-12 CN CN2009801278952A patent/CN102089009B/zh active Active
- 2009-06-12 EP EP09762071.0A patent/EP2303333B1/en active Active
- 2009-06-12 PT PT97620710T patent/PT2303333E/pt unknown
- 2009-06-12 NZ NZ590089A patent/NZ590089A/xx unknown
- 2009-06-12 US US12/997,411 patent/US20110142876A1/en not_active Abandoned
- 2009-06-12 BR BRPI0915517A patent/BRPI0915517B8/pt active IP Right Grant
- 2009-06-12 HU HUE09762071A patent/HUE025512T2/hu unknown
- 2009-06-12 WO PCT/IB2009/006285 patent/WO2009150543A2/en active Application Filing
- 2009-06-12 ES ES09762071.0T patent/ES2537019T3/es active Active
- 2009-06-12 DK DK09762071.0T patent/DK2303333T3/da active
- 2009-06-12 SI SI200931193T patent/SI2303333T1/sl unknown
- 2009-06-12 AU AU2009259017A patent/AU2009259017B2/en active Active
- 2009-06-12 CA CA2727565A patent/CA2727565C/en active Active
-
2010
- 2010-12-23 ZA ZA2010/09304A patent/ZA201009304B/en unknown
-
2012
- 2012-10-26 US US13/661,409 patent/US9475846B2/en active Active
-
2015
- 2015-05-11 CY CY20151100416T patent/CY1116379T1/el unknown
- 2015-05-18 HR HRP20150527TT patent/HRP20150527T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0915517B8 (pt) | 2021-05-25 |
GB0810894D0 (en) | 2008-07-23 |
SI2303333T1 (sl) | 2015-06-30 |
PT2303333E (pt) | 2015-06-08 |
US20110142876A1 (en) | 2011-06-16 |
ES2537019T3 (es) | 2015-06-01 |
BRPI0915517A2 (pt) | 2017-06-20 |
AU2009259017A1 (en) | 2009-12-17 |
EP2303333A2 (en) | 2011-04-06 |
HUE025512T2 (hu) | 2016-05-30 |
AU2009259017B2 (en) | 2014-12-11 |
ZA201009304B (en) | 2012-08-29 |
HRP20150527T1 (en) | 2015-06-19 |
US20130142822A1 (en) | 2013-06-06 |
US9475846B2 (en) | 2016-10-25 |
WO2009150543A3 (en) | 2010-05-06 |
DK2303333T3 (da) | 2015-05-26 |
PL2303333T3 (pl) | 2015-11-30 |
BRPI0915517B1 (pt) | 2020-10-06 |
CN102089009A (zh) | 2011-06-08 |
CA2727565C (en) | 2017-01-10 |
CA2727565A1 (en) | 2009-12-17 |
WO2009150543A2 (en) | 2009-12-17 |
NZ590089A (en) | 2012-12-21 |
EP2303333B1 (en) | 2015-02-18 |
CY1116379T1 (el) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023036953A (ja) | 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強 | |
CN102089009B (zh) | 偶联的Vi糖 | |
US10758604B2 (en) | Methods for the prevention of Salmonella infections | |
TR201811681T4 (tr) | İmmünojenik bileşimler. | |
US10098947B2 (en) | Salmonella conjugate vaccines | |
ES2495744T5 (es) | Glucanos con adyuvante | |
CN104080479A (zh) | 包括spr0096和spr2021抗原的运载体分子 | |
US9439955B2 (en) | Conjugated β-1,3-linked glucans | |
CN105307684A (zh) | 非直链糖缀合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis Vaccines & Diagnostic |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170728 Address after: Belgium Sutter Rixon Patentee after: Glazo Smithkline Beecham Biologicals S. A. Address before: Basel Patentee before: Novartis Ag |